ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 157-170

  Song, G W ^a   Lee, S G ^a   Hwang, S ^a   Kim, K H ^a   Ahn, C S ^a   Moon, D B ^a   Ha, T Y ^a   Jung, D H ^a   Park, G C ^a   Kim, W J ^a   Sin, M H ^a   Yoon, Y I ^a   Kang, W H ^a   Kim, S H ^a   Tak, E Y ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RITUXIMAB; BLOOD GROUP ABO SYSTEM; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CHOLESTASIS; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; RETRANSPLANTATION; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; SPLENECTOMY; SURVIVAL RATE; ADOLESCENT; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; GRAFT REJECTION; IMMUNOLOGY; LIVER DISEASES; PROGNOSIS; YOUNG ADULT;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RITUXIMAB; SURVIVAL RATE; YOUNG ADULT;

EID: 84956888950     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13444     Document Type: Article

References (42)

1. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE., Liver transplantation across ABO blood groups. Surgery 1986; 100: 342-348.
2. Gugenheim J, Samuel D, Reynes M, Bismuth H., Liver transplantation across ABO blood group barriers. Lancet 1990; 336: 519-523.
3. Demetris AJ, Jaffe R, Tzakis A, et al., Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132: 489-502.
4. Raut V, Uemoto S., Management of ABO-incompatible living-donor liver transplantation: Past and present trends. Surg Today 2011; 41: 317-322.
5. Egawa H, Teramukai S, Haga H, et al., Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: A Japanese multicenter study. Am J Transplant 2014; 14: 102-114.
6. Song GW, Lee SG, Hwang S, et al., Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. J Hepatol 2014; 61: 575-582.
7. Wu J, Ye S, Xu X, Xie H, Zhou L, Zheng S., Recipient outcomes after ABO-incompatible liver transplantation: A systematic review and meta-analysis. PLoS One 2011; 6: e16521.
8. Song GW, Lee SG, Hwang S, et al., Section 15. A desensitizing protocol without local graft infusion therapy and splenectomy is a safe and effective method in ABO-incompatible adult LDLT. Transplantation 2014; 97 (Suppl 8): S59-S66.
9. Egawa H, Ohmori K, Haga H, et al., B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007; 13: 579-588.
10. Egawa H, Ohdan H, Haga H, et al., Current status of liver transplantation across ABO blood-type barrier. J Hepatobiliary Pancreat Surg 2008; 15: 131-138.
11. Egawa H, Oike F, Buhler L, et al., Impact of recipient age on outcome of ABO incompatible living-donor liver transplantation. Transplantation 2004; 77: 403-411.
12. Haga H, Egawa H, Shirase T, et al., Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 16-27.
13. Haga H, Egawa H, Fujimoto Y, et al., Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457-464.
14. Cameron AM, Busuttil RW., Ischemic cholangiopathy after liver transplantation. Hepatobiliary Pancreat Dis Int 2005; 4: 495-501.
15. Deltenre P, Valla DC., Ischemic cholangiopathy. Semin Liver Dis 2008; 28: 235-246.
16. Hwang S, Lee SG, Lee YJ, et al., Lessons learned from 1,000 living donor liver transplantations in a single center: How to make living donations safe. Liver Transpl 2006; 12: 920-927.
17. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M., Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008; 47: 143-152.
18. Kim JM, Kwon CH, Joh JW, et al., ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor. J Hepatol 2013; 59: 1215-1222.
19. Kim BW, Park YK, Kim YB, Wang HJ, Kim MW., Effects and problems of adult ABO-incompatible living donor liver transplantation using protocol of plasma exchange, intra-arterial infusion therapy, and anti-CD20 monoclonal antibody without splenectomy: Case reports of initial experiences and results in Korea. Transplant Proc 2008; 40: 3772-3777
20. Ikegami T, Taketomi A, Soejima Y, et al., Rituximab, IVIG, and plasma exchange without graft local infusion treatment: A new protocol in ABO incompatible living donor liver transplantation. Transplantation 2009; 88: 303-307.
21. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP., The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407.
22. Tzvetanov I, Spaggiari M, Jeon H, et al., Rescue splenectomy in a case of humoral rejection in ABO-incompatible simultaneous liver-kidney transplantation. Transplantation 2012; 93: e1-e2.
23. Raut V, Mori A, Kaido T, et al., Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012; 93: 99-105.
24. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K., Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22: 447-454.
25. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G., Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
26. Uchiyama H, Mano Y, Taketomi A, et al., Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. Transplantation 2011; 92: 1134-1139.
27. Winters JL., Plasma exchange: Concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program 2012; 2012: 7-12.
28. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA., Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-1208.
29. Puisset F, White-Koning M, Kamar N, et al., Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013; 76: 734-740.
30. Darabi K, Berg AH., Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125: 592-597.
31. Lee SD, Kim SH, Kong SY, Kim YK, Park SJ., Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transpl Immunol 2015; 32: 29-34.
32. Boberg KM, Foss A, Midtvedt K, Schrumpf E., ABO-incompatible deceased donor liver transplantation with the use of antigenspecificimmunoadsorption and anti-CD20 monoclonal antibody. Clin Transplant 2006; 20: 265-268.
33. Maitta RW, Choate J, Emre SH, Luczycki SM, Wu Y,. Emergency ABO-incompatible liver transplant secondary to fulminant hepatic failure: Outcome, role of TPE and review of the literature. J Clin Apher 2012; 27: 320-329.
34. Shen T, Lin BY, Jia JJ, et al., A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int 2014; 13: 395-401.
35. Salah A, Fujimoto M, Yoshizawa A, et al., Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation. Liver Transpl 2014; 20: 200-209.
36. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ., C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739-749.
37. Schmeding M, Dankof A, Krenn V, et al., C4d in acute rejection after livertransplantation-a valuable tool in differential diagnosisto hepatitis C recurrence. Am J Transplant 2006; 6: 523-530.
38. Mor E, Skerrett D, Manzarbeitia C, et al., Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995; 59: 986-990.
39. Skogsberg U, Breimer ME, Friman S, et al., Adult ABO-incompatible liver transplantation, using A and B donors. Xenotransplantation 2006; 13: 154-159.
40. Perry DK, Burns JM, Pollinger HS, et al., Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-209.
41. Flechner SM, Fatica R, Askar M, et al., The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-1492.
42. Tzvetanov I, Spaggiari M, Joseph J, et al., The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: Report of three cases and review of literature. Transplant Proc 2012; 44: 2971-2975.